Hit enter to search or ESC to close
Hepion PharmaceuticalsHepion Pharmaceuticals
  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers
Hepion Pharmaceuticals

Robert Foster Discusses Drug Development on Humble & Fred Morning Radio Podcast

By HepionAugust 27, 2020December 2nd, 2020Media Placements
No Comments
https://hepionpharma.com/wp-content/uploads/2020/08/Humble-and-Fred-200827-dr-robert-foster-clip.mp3
DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
March 23, 2021

Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
March 22, 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
March 11, 2021

Share Tweet Share Pin
Get Important News and Updates by Email Subscribe

© 2021 Hepion Pharmaceuticals | Disclaimer & Terms of Use | WDDI

  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers